Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant

Completed

• Conditions: Hematopoietic Stem Cell Transplantation; Transplantation, Hematopoietic Stem Cell; Stem Cell Transplantation, Hematopoietic

• Registration Number: NCT02414113
• Lead Sponsor: Washington University School of Medicine

Brief Summary

Before considering high-GVHD Negative Outcome Score (GNOS) donor selection for routine clinical practice, this blinded prospective study will be carried out for assessment of severe GVHD (graft-versus-host-disease) reduction associated with selecting high-GNOS donors for allogeneic hematopoietic peripheral blood stem cell transplant. The objective of this prospective study is to show: (a) that GVHD reductions and donor availabilities as observed in the retrospective studies also apply to prospective samples that are collected and processed from on-going matched unrelated transplants, and (b) that high-GNOS donor selection readily fits into today's donor selection process, such as to facilitate access to the benefits of GVHD reduction. The prospective study is designed to be blinded, and will not involve specific donor selection nor any influence on clinical management or decision making by application of the GNOS technology.

To determine if some GNOS models perform better than others across different clinical centers, or across different recipient / donor attributes, 4 different specific GNOS models will be evaluated. Bootstrap computational analyses have been carried out on the retrospective data for the 4 GNOS models and will be tested and validated in this prospective study.

Detailed Description

Enrollment of the recipient will occur prior to the unrelated donor search or haploidentical donor identification.

FOR UNRELATED DONORS:

When the unrelated donor search is formalized, the study team will submit a study participation request document to the NMDP for all potential donors that are being evaluated for an enrolled recipient. These documents will be relayed to the appropriate donor centers by the NMDP. This document informs the donor center that the potential donor's participation in this trial is being requested. The donor center then will approach the potential donor about participation in the trial. If the potential donor consents to participate, the required donor study samples will be obtained and shipped to the appropriate labs. This will conclude the potential donor's physical participation in the trial. The donor consent will be kept at the donor center and will not be provided to the investigator.

FOR HAPLOIDENTICAL DONORS:

Haploidentical donors will be identified by the transplant team caring for the recipient, and will follow the site's standard procedures for identification, HLA typing, and medical clearance for stem cell donation. Haploidentical donors will be approached by the transplant team or the study coordinator about participation in the trial. If the potential donor consents to participate, the required donor study samples will be obtained and shipped to the appropriate lab for processing prior to the start of growth factor for stem cell mobilization or prior to stem cell collection via bone marrow harvest.

FOR ALL DONORS:

At the time of HLA confirmatory typing, 24 mL of whole blood will be collected from donors.

Study Timeline

• Study Start: 2015-03-25
• Study First Submitted: 2015-04-07
• Study First Submitted QC: 2015-04-09
• Study First Posted: 2015-04-10
• Primary Completion: 2020-04-29
• Study Completion: 2021-01-21
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-02
• Last Update Posted: 2021-02-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 113

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rates of grade III-IV aGVHD (acute graft-versus-host disease) in hematopoietic stem cell transplantation (HSCT) performed with high GNOS versus low GNOS donors	100 days after HSCT	* "GNOS" refers to PBD's proprietary "GVHD Negative Outcome Score" technology for reduction of grades III \& IV aGVHD through donor selection. GNOS is a gene expression-based signature of lower donor allo-reactivity such that transplanted cells from donors displaying higher GNOS will exhibit less allo-reactivity against recipient tissues, therefore decreasing the incidence of severe GVHD. GNOS is determined from pre-transplant, pre-mobilization gene expression profiling of donor CD4 cells from a blood draw.; * Incidence and severity of acute GVHD will be assessed based on the modified Glucksberg criteria and Seattle criteria. Attempts should be made to confirm the diagnosis pathologically by biopsy of target organ(s) as per standard of care.

Secondary Outcome Measures

Name	Time	Method
Overall survival in HSCT performed with high GNOS versus low GNOS donor who experienced Grades 0-II and Grades III-IV aGVHD during the first 100 days after HSCT	3 months	-Overall survival (OS) is defined as the date of transplant to the date of death from any cause.
Relapse rates after HSCTs performed with high GNOS versus low GNOS donors	1 year	-A patient will be considered relapsed when there is a recurrence of the original malignant disease after transplantation
Performance of 4 pre-defined GNOS models	100 days after HSCT	* The main variables' association of interest, for any of the 4 outcome predictive models being employed, is recipient aGVHD Grades {0, I, II} exclusive-or Grades {III-IV} vs. donor GNOS level. The analyses will be done separately for each of the 4 different outcome predictive models that have been employed in the study.; * The GNOS values from each of 4 models will be determined by PBD and will be kept confidential and blinded from the investigators. PBD will not know the recipient health data (GVHD occurrence, PFS, OS, etc.) when the GNOs analysis is performed. Thus, a given donor's GNOS values from the 4 different models and the corresponding recipient's outcomes will not be correlated until after unblinding.

Trial Locations

Locations (4)

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States

UNC Hospitals; 🇺🇸 Chapel Hill, North Carolina, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center; 🇺🇸 Columbus, Ohio, United States